QIMR Berghofer researchers have discovered a potential new cancer immunotherapy target that involves switching off a regulatory cell to stop tumours growing and spreading.
The study findings have been published today in Cancer Discovery, a journal of the American Association for Cancer Research.
Senior researcher and head of QIMR Berghofer’s Cancer Immunoregulation and Immunotherapy Laboratory, Associate Professor Michele Teng, said in future the discovery could potentially help treat patients with cancers where other current immunotherapies have not worked.
“Our work on mice shows for the first time that many tumours display the molecule MR1 on their cell surface, and when it’s present, this molecule turns on an important regulatory cell that prevents the body’s own immune system from fighting the cancer,” Associate Professor Teng said.
“We found if a type of regulatory cell called MAIT (mucosal-associated invariant T) cells are turned on, they stop immune or white blood cells known as T and NK cells from attacking and killing off tumour cells.
“The cancer is effectively creating its own defence mechanism to evade immune attack and survive. The display of MR1 activates the MAIT cells, which in turn switch off cancer-fighting T and NK cells.
“While other regulatory cells of the immune system are known to stop T and NK cells from killing tumour cells, this is the first time it’s been shown that these regulatory MAIT cells can do this job.”
Associate Professor Teng said her team found that by giving mice an antibody that blocked MR1, this stopped the MAIT cells from becoming activated, and the T and NK cells could respond, slowing cancer growth and stopping it spreading.
“This work demonstrates that antibodies that block MR1 could in future be an effective new immunotherapy,” Associate Professor Teng said.
“It probably won’t work on every cancer, but it looks like it could be effective in treating cancers that can display the MR1 molecule. It also means this display of MR1 could be used to screen which patients would respond to this immunotherapy.
“We now need to replicate this research in humans.”
Associate Professor Teng said while the research was at a very early stage and required more work, it was promising.
“The next step is to try to understand what kind of human tumours display MR1 as a protective mechanism, which would then help us identify which tumours would respond best to MR1-blocking immunotherapy,” she said.
“Immunotherapies have been effectively used to treat more than 15 different cancer types but the proportion of patients that respond for each cancer can differ.
“In patients with advanced melanoma for example, current approved immunotherapies work in about 50 per cent of cases, but half do not respond, and that’s why we need to find new therapies.”
Learn more: POTENTIAL NEW CANCER TREATMENT A STEP CLOSER
Go deeper with Bing News on:
Cancer immunotherapy
- CAR T-Cell therapy revolutionised landscape of cancer treatment: Doctors
A 42-year-old man from Bengaluru has successfully achieved "durable remission" from a relapsed cancer viaCAR T-cell therapy, said doctors on Tuesday hailing it as a revolutionary cancer treatment.
- Exercise, therapy and diet can all improve life during cancer treatment and boost survival. Here’s how
The mainstays of cancer treatment remain surgery, chemotherapy, radiation, immunotherapy, targeted therapy, and hormone therapy. But exercise, psychological support and diet can be powerful adjuncts.
- Innovative organ-on-a-chip technology could shed light on cell behavior in liver cancer
In a stride toward enhancing cancer treatment, University of Birmingham researchers are using organ-on-a-chip technology to imitate the liver's environment and improve immunotherapy for liver cancer.
- Personalized cancer vaccine: Researchers in Pittsburgh discuss possible future breakthrough
Pittsburgh's Action News 4 spoke with local researchers about a potential major breakthrough in cancer treatment. They're discussing a personalized vaccine that has been showing dramatic results in ...
- Research finds VISTA directly blocks T-cells from functioning in immunotherapy
A team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The study explains ...
Go deeper with Google Headlines on:
Cancer immunotherapy
[google_news title=”” keyword=”cancer immunotherapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Blocking immunotherapy
- Cancer survivor sees how Race for Life Portsmouth is helping scientists find new treatments
A bladder cancer survivor is calling on Portsmouth to support Race for Life on June 29 and June 30 after seeing first-hand how funds raised can help the region’s researchers find the best new cancer ...
- Research finds VISTA directly blocks T-cells from functioning in immunotherapy
A team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment. The study explains ...
- Unlocking the body's defenses: Understanding immunotherapy
In the battle against diseases, the human body boasts an intricate defense network capable of identifying and neutralizing threats—the immune system. It serves as a guardian, constantly patrolling the ...
- Immunotherapy for Peanut Allergies Still a Work in Progress
Why can’t people see an allergist and get desensitized to a peanut allergy? As a child, I was allergic to dust, pet hair, milk and other things, but I received treatments.
- Unlocking The Body's Defences: Understanding Immunotherapy
In the battle against diseases, the human body boasts an intricate defence network capable of identifying and neutralising threats – the immune syst ...
Go deeper with Google Headlines on:
Blocking immunotherapy
[google_news title=”” keyword=”blocking immunotherapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]